These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2418131

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. (2'-5')oligo(A) synthetase as a monitor of interferon action in juvenile laryngeal papillomatosis.
    Lodemann E, Kornhuber B, Gerein V, von Il'berg C.
    J Interferon Res; 1984; 4(2):283-90. PubMed ID: 6747349
    [Abstract] [Full Text] [Related]

  • 3. Interferon and 2',5'-oligo(A) synthetase activities in serum and blood mononuclear leukocytes of cattle after injection of bovine interferon-alpha 1.
    Perino LJ, Short EC, Burge LJ, Winter DA, Fulton RW.
    Am J Vet Res; 1990 Jun; 51(6):886-92. PubMed ID: 1695068
    [Abstract] [Full Text] [Related]

  • 4. [Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].
    Sokolova TM, Lopatina OA, Nosik NN, Cheshik SG.
    Biull Eksp Biol Med; 1993 Jun; 115(6):633-4. PubMed ID: 7690616
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
    Moritz T, Weissmann B, Grünewald B, Hust H, Kummer G, Niederle N.
    Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
    Grups JW, Komprecht B.
    J Biol Regul Homeost Agents; 1989 Jun; 3(3):98-101. PubMed ID: 2516404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.
    Merritt JA, Borden EC, Ball LA.
    J Interferon Res; 1985 Jun; 5(1):191-8. PubMed ID: 3989336
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
    Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU.
    Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
    [Abstract] [Full Text] [Related]

  • 14. 2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
    Merritt JA, Meltzer DM, Ball LA, Borden EC.
    Prog Clin Biol Res; 1985 Sep; 202():423-30. PubMed ID: 3832076
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo 2',5'-oligoadenylate synthetase activity induced by recombinant DNA-derived bovine interferon alpha I1 in bovine alveolar macrophages and blood mononuclear cells.
    Holland SP, Fulton RW, Short EC, Wyckoff JH, Fox JC.
    Am J Vet Res; 1991 Nov; 52(11):1779-83. PubMed ID: 1664669
    [Abstract] [Full Text] [Related]

  • 16. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G.
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [Abstract] [Full Text] [Related]

  • 17. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
    Witter F, Barouki F, Griffin D, Nadler P, Woods A, Wood D, Lietman P.
    Clin Pharmacol Ther; 1987 Nov; 42(5):567-75. PubMed ID: 2445516
    [Abstract] [Full Text] [Related]

  • 18. Interferon and 2-5A synthetase in patients with immune diseases.
    Preble OT, Yeh TJ, Silverman RH, Klippel JH, Straus SE, Gelmann EP.
    Prog Clin Biol Res; 1985 Nov; 202():415-22. PubMed ID: 2421319
    [No Abstract] [Full Text] [Related]

  • 19. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
    Sturgill MG, Rashidbaigi A, Liao MJ, Zhao XX, Hua J, Trout R, Knill JR, Grasing KW.
    J Clin Pharmacol; 2000 Jun; 40(6):606-15. PubMed ID: 10868311
    [Abstract] [Full Text] [Related]

  • 20. A comparison of interferon levels with leukocyte (2'-5') oligoadenylate synthetase activity as markers of viral encephalopathies.
    Kennedy CR, Tilles JG.
    J Interferon Res; 1988 Oct; 8(5):609-15. PubMed ID: 2466911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.